02/18/2021 | Press release | Distributed by Public on 02/18/2021 02:06
THIS ANNOUNCEMENT CONTAINS REGULATED INFORMATION
Acacia Pharma Group plc
Change of EU home Member State
Cambridge, UK and Indianapolis, US - 18 February 2021, 09:00 CET: Acacia Pharma Group plc ('Acacia Pharma' or the 'Company') (EURONEXT: ACPH), a commercial stage biopharmaceutical company focused on developing and commercializing novel products to improve the care of patients undergoing serious medical treatments such as surgery, invasive procedures, or chemotherapy, announces a change of its home Member State to Belgium.
Following the end of the United Kingdom's transition period for leaving the European Union on 31 December 2020, the United Kingdom can no longer be the home Member State of Acacia Pharma for the purposes of Directive 2004/109/EC of 15 December 2004 on the harmonization of transparency requirements in relation to information about issuers whose securities are admitted to trading on a regulated market and amending Directive 2001/34/EC (the EU Transparency Directive).
Acacia Pharma hereby announces that it has chosen Belgium as its home Member State in accordance with article 10, §3, of the Belgian Act of 2 August 2002 regarding financial supervision and financial services. The Company has given due notice of this change to the Belgian Financial Services and Markets Authority (the 'Belgian FSMA').
Acacia Pharma continues to be traded on the regulated market of Euronext Brussels.
Acacia Pharma Group plc
The Officers' Mess, Royston Road, Duxford, Cambridge, CB22 4QH, United Kingdom
Company number 9759376
About Acacia Pharma
Acacia Pharma is a hospital pharmaceutical company focused on the development and commercialization of new products aimed at improving the care of patients undergoing significant treatments such as surgery, other invasive procedures, or cancer chemotherapy. The Company has identified important and commercially attractive unmet needs in these areas that its product portfolio aims to address.
Acacia Pharma's first product, BARHEMSYS® (amisulpride injection) is marketed in the US for the management of postoperative nausea & vomiting (PONV).
BYFAVO™ (remimazolam) for injection, a very rapid onset/offset IV benzodiazepine sedative is approved and launched in the US for use during invasive medical procedures in adults lasting 30 minutes or less, such as colonoscopy and bronchoscopy. BYFAVO is in-licensed from Paion UK Limited for the US market.
APD403 (intravenous and oral amisulpride), a selective dopamine antagonist for chemotherapy induced nausea & vomiting (CINV) has successfully completed one proof-of-concept and one Phase 2 dose-ranging study in patients receiving highly emetogenic chemotherapy.
Acacia Pharma has its US headquarters in Indianapolis, IN and its R&D operations are centered in Cambridge, UK. The Company is listed on the Euronext Brussels exchange under the ISIN code GB00BYWF9Y76 and ticker symbol ACPH.